Update on current care guidelines : multiple sclerosis
Treatment for relapsing-remitting multiple sclerosis (RRMS) is initiated upon fulfillment of new McDonald 2010 criteria for RRMS. Patients with clinically isolated syndrome and at high-risk for RRMS are followed by magnetic resonance imaging to confirm the diagnosis of RRMS as early as possible. Interferon-beta and glatiramer acetate are the first-line immunomodulating drugs (IMD) for RRMS. If the disease is active according to clinical or MRI evaluation during the first-line IMD treatment, fingolimod or natalizumab may be considered as second-line therapies. IMD is discontinued upon the transition of RRMS to secondary progressive phase.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:129 |
|---|---|
| Enthalten in: |
Duodecim; laaketieteellinen aikakauskirja - 129(2013), 5 vom: 10., Seite 548-9 |
| Sprache: |
Finnisch |
|---|
| Weiterer Titel: |
MS-tauti |
|---|
| Anmerkungen: |
Date Completed 20.06.2013 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM226051838 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM226051838 | ||
| 003 | DE-627 | ||
| 005 | 20231224070544.0 | ||
| 007 | tu | ||
| 008 | 231224s2013 xx ||||| 00| ||fin c | ||
| 028 | 5 | 2 | |a pubmed24n0753.xml |
| 035 | |a (DE-627)NLM226051838 | ||
| 035 | |a (NLM)23520898 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fin | ||
| 245 | 1 | 0 | |a Update on current care guidelines |b multiple sclerosis |
| 246 | 3 | 3 | |a MS-tauti |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 20.06.2013 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Treatment for relapsing-remitting multiple sclerosis (RRMS) is initiated upon fulfillment of new McDonald 2010 criteria for RRMS. Patients with clinically isolated syndrome and at high-risk for RRMS are followed by magnetic resonance imaging to confirm the diagnosis of RRMS as early as possible. Interferon-beta and glatiramer acetate are the first-line immunomodulating drugs (IMD) for RRMS. If the disease is active according to clinical or MRI evaluation during the first-line IMD treatment, fingolimod or natalizumab may be considered as second-line therapies. IMD is discontinued upon the transition of RRMS to secondary progressive phase | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Natalizumab |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a Propylene Glycols |2 NLM | |
| 650 | 7 | |a Glatiramer Acetate |2 NLM | |
| 650 | 7 | |a 5M691HL4BO |2 NLM | |
| 650 | 7 | |a Interferon-beta |2 NLM | |
| 650 | 7 | |a 77238-31-4 |2 NLM | |
| 650 | 7 | |a Fingolimod Hydrochloride |2 NLM | |
| 650 | 7 | |a G926EC510T |2 NLM | |
| 650 | 7 | |a Sphingosine |2 NLM | |
| 650 | 7 | |a NGZ37HRE42 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Duodecim; laaketieteellinen aikakauskirja |d 1945 |g 129(2013), 5 vom: 10., Seite 548-9 |w (DE-627)NLM000016136 |x 0012-7183 |7 nnns |
| 773 | 1 | 8 | |g volume:129 |g year:2013 |g number:5 |g day:10 |g pages:548-9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 129 |j 2013 |e 5 |b 10 |h 548-9 | ||